LIVIVO - Search results -

Search results

Result 1 - 10 of total 50

Search options

Article: The role of microRNA in cancer cachexia and muscle wasting: A review article.

Sutandyo, Noorwati

2021 Volume 12, Issue 2, Page(s) 124–128

Abstract: Almost half of cancer patients experience cachexia syndrome. Cachexic patients are at risk of increased side effects of chemotherapy, reduced tolerance to chemotherapy drugs, longer duration of treatment period, and decreased quality of life. Cancer ... ...

Abstract	Almost half of cancer patients experience cachexia syndrome. Cachexic patients are at risk of increased side effects of chemotherapy, reduced tolerance to chemotherapy drugs, longer duration of treatment period, and decreased quality of life. Cancer cachexia is a multifactorial syndrome. Micro ribonucleic acid (miRNA), a "non-coding RNA", is considered to be a risk factor of cachexia and muscle wasting in cancer patients. miRNA has a role in affecting protein regulation, associated with different inflammatory and disease pathways. miRNA can also affect cytokines or directly change the regulation of metabolism that lead to cachexia. In this review, we want to focus on the pathophysiology to give a better understanding about the role of miRNA in the development of cancer cachexia. Based on various pathways of miRNA in cancer cachexia, it can be a potential target for therapeutic strategies. Improved knowledge about miRNA can give the opportunity to develop new treatment in the management of cancer cachexia.
Language	English
Publishing date	2021-05-12
Publishing country	Iran
Document type	Journal Article ; Review
ZDB-ID	2971933-1
ISSN	2008-6172 ; 2008-6164
ISSN (online)	2008-6172
ISSN	2008-6164
DOI	10.22088/cjim.12.2.124
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Beneficial Roles of Physical Activity in Cancer Prevention

Noorwati Sutandyo

International Journal of Medical Reviews and Case Reports, Vol 5, Iss 1, Pp 43-

2021 Volume 47

Abstract: Cancer is a multifactorial disease resulting from the combination of the host (genetics, age, sex), environmental (viruses, radiation), and lifestyle factors (nutrition, physical activity, alcohol, smoking). While it is still the leading cause of death ... ...

Abstract	Cancer is a multifactorial disease resulting from the combination of the host (genetics, age, sex), environmental (viruses, radiation), and lifestyle factors (nutrition, physical activity, alcohol, smoking). While it is still the leading cause of death in developing countries and is the second leading cause of death in developed countries, there has been significant progress in our understanding of cancer etiology, early detection, treatment, and prevention in the past few decades. Physical activity, one of the modified lifestyle risk factors, is the lifestyle intervention opportunities of concern as nearly a quarter of the global adult population performs less than recommended physical activity. The World Cancer Research Fund in 2018 concluded that physical activity is strongly associated with a reduced risk of colorectal and breast, which are two cancer types with high mortality rates globally. Here we will explain various plausible biological mechanisms that link physical activity to the reduction of cancer risks categorized as an alteration in endocrine, immune function, metabolic, and oxidative stress levels, resulting in direct inhibition of receptors binding and reduce inflammatory conditions that support the development of cancer cells.
Keywords	cancer ; physical activity ; prevention ; Medicine ; R
Subject code	610
Language	English
Publishing date	2021-01-01T00:00:00Z
Publisher	Bulgarian Association of Young Surgeons
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: The Role of microRNA in Cancer Cachexia and Muscle Wasting

Noorwati Sutandyo

Caspian Journal of Internal Medicine, Vol 12, Iss 2, Pp 124-

A Review Article

2021 Volume 128

Abstract	Almost half of cancer patients experience cachexia syndrome. Cachexic patients are at risk of increased side effects of chemotherapy, reduced tolerance to chemotherapy drugs, longer duration of treatment period, and decreased quality of life. Cancer cachexia is a multifactorial syndrome. Micro ribonucleic acid (miRNA), a “non-coding RNA”, is considered to be a risk factor of cachexia and muscle wasting in cancer patients. miRNA has a role in affecting protein regulation, associated with different inflammatory and disease pathways. miRNA can also affect cytokines or directly change the regulation of metabolism that lead to cachexia. In this review, we want to focus on the pathophysiology to give a better understanding about the role of miRNA in the development of cancer cachexia. Based on various pathways of miRNA in cancer cachexia, it can be a potential target for therapeutic strategies. Improved knowledge about miRNA can give the opportunity to develop new treatment in the management of cancer cachexia.
Keywords	micro rna ; cancer ; cachexia ; muscle wasting ; Internal medicine ; RC31-1245
Subject code	610
Language	English
Publishing date	2021-03-01T00:00:00Z
Publisher	Babol University of Medical Sciences
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Prognostic Values of CD8+, PARP, and EGFR on Overall Survival in Patients with Triple-Negative Breast Cancer.

Putri, Rizky Ifandriani / Haryono, Samuel J / Brahma, Bayu / Prayitno, Yuniar Harris / Sutandyo, Noorwati

Asian Pacific journal of cancer prevention : APJCP

2024 Volume 25, Issue 3, Page(s) 1025–1034

Abstract: Objective: This study aimed to investigate the associations of CD8+, PARP, and EGFR expressions with two-year survival in patients with triple-negative breast cancer (TNBC).: Methods: A retrospective cohort study was conducted in a national cancer ... ...

Abstract	Objective: This study aimed to investigate the associations of CD8+, PARP, and EGFR expressions with two-year survival in patients with triple-negative breast cancer (TNBC). Methods: A retrospective cohort study was conducted in a national cancer center. All patients aged 18 years diagnosed with TNBC (2013-2017) were included and followed for 24 months or until the patients were deceased. Kaplan-Meier survival function and Cox proportional hazard model were applied for the analyses. Results: The study population was followed for 24 months (2,692 person-months, N = 126). At the end of the follow-up, 27 patients were deceased. The two-year mortality rate was 10 per 1,000 person-month. Kaplan-Meier graphs showed that after approximately one year of follow-up, poorer survival was seen in patients with low CD8+, positive PARP, and positive EGFR. The adjusted analysis found staging as the main predictor of overall survival in TNBC (HR = 7.20, 95% CI= 2.07 - 25.00). Conclusions: Patients with low CD8+, positive PARP, and positive EGFR expressions seem to be associated with poorer overall survival in TNBC. After approximately one year of follow-up, higher survival was observed in patients with high CD8+, negative PARP, and negative EGFR. Staging remains the main predictor of TNBC survival. Therefore, early detection and treatment of TNBC are essential to improve survival.
MeSH term(s)	Humans ; Prognosis ; Poly(ADP-ribose) Polymerase Inhibitors ; Triple Negative Breast Neoplasms/metabolism ; Retrospective Studies ; ErbB Receptors/metabolism ; CD8-Positive T-Lymphocytes/metabolism ; Kaplan-Meier Estimate
Chemical Substances	Poly(ADP-ribose) Polymerase Inhibitors ; ErbB Receptors (EC 2.7.10.1) ; EGFR protein, human (EC 2.7.10.1)
Language	English
Publishing date	2024-03-01
Publishing country	Thailand
Document type	Journal Article
ZDB-ID	2218955-5
ISSN	2476-762X ; 1513-7368
ISSN (online)	2476-762X
ISSN	1513-7368
DOI	10.31557/APJCP.2024.25.3.1025
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: New Paradigm in Treating Cancer: Right on Target.

Sutandyo, Noorwati

Acta medica Indonesiana

2016 Volume 48, Issue 2, Page(s) 139–144

Abstract: Cancer prevalence is increasing every year and now cancer is the third highest cause of death in developing countries. Effective anticancer treatment can prolong life and improve the patient's quality of life. Targeted therapy is a new therapeutic ... ...

Abstract	Cancer prevalence is increasing every year and now cancer is the third highest cause of death in developing countries. Effective anticancer treatment can prolong life and improve the patient's quality of life. Targeted therapy is a new therapeutic modality which targets specific molecules in the cancer cell and disrupts dysregulated signaling pathways involved in carcinogenesis. Since targeted therapy does not attack normal cells, its side effects are considered low compared to chemotherapy. More than 15 drugs have been approved for treatment in various human cancers. These drugs can largely be grouped into tyrosine kinase inhibitors and monoclonal antibodies. This review will focus on the most common agents within both groups.
MeSH term(s)	Antibodies, Monoclonal/therapeutic use ; Humans ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/classification ; Molecular Targeted Therapy/economics ; Neoplasms/drug therapy ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Quality of Life ; Signal Transduction/drug effects
Chemical Substances	Antibodies, Monoclonal ; Protein-Tyrosine Kinases (EC 2.7.10.1)
Language	English
Publishing date	2016-04
Publishing country	Indonesia
Document type	Journal Article ; Review
ZDB-ID	2474707-5
ISSN	2338-2732 ; 0125-9326
ISSN (online)	2338-2732
ISSN	0125-9326
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6834: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: New Paradigm in Treating Cancer

Noorwati Sutandyo

Acta Medica Indonesiana, Vol 48, Iss

Right on Target

2016 Volume 2

Abstract: Cancer prevalence is increasing every year and now cancer is the third highest cause of death in developing countries. Effective anticancer treatment can prolong life and improve the patient’s quality of life. Targeted therapy is a new therapeutic ... ...

Abstract	Cancer prevalence is increasing every year and now cancer is the third highest cause of death in developing countries. Effective anticancer treatment can prolong life and improve the patient’s quality of life. Targeted therapy is a new therapeutic modality which targets specific molecules in the cancer cell and disrupts dysregulated signaling pathways involved in carcinogenesis. Since targeted therapy does not attack normal cells, its side effects are considered low compared to chemotherapy. More than 15 drugs have been approved for treatment in various human cancers. These drugs can largely be grouped into tyrosine kinase inhibitors and monoclonal antibodies. This review will focus on the most common agents within both groups.
Keywords	anticancer therapy ; monoclonal antibodies ; targeted therapy ; tyrosine kinase inhibitors ; Internal medicine ; RC31-1245
Language	English
Publishing date	2016-09-01T00:00:00Z
Publisher	Interna Publishing
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Comparison of early mortality between leukapheresis and non-leukapheresis in adult acute myeloid leukemia patients with hyperleukocytosis: a systematic review and meta-analysis.

Rinaldi, Ikhwan / Sutandyo, Noorwati / Winston, Kevin

Hematology (Amsterdam, Netherlands)

2022 Volume 27, Issue 1, Page(s) 141–149

Abstract: Objectives: One of the treatment modalities that can be used for hyperleukocytosis is leukapheresis. However, the result of studies showing the benefit of early mortality through the use of leukapheresis versus no leukapheresis is still inconclusive. ... ...

Abstract	Objectives: One of the treatment modalities that can be used for hyperleukocytosis is leukapheresis. However, the result of studies showing the benefit of early mortality through the use of leukapheresis versus no leukapheresis is still inconclusive. Hence, we aimed to conduct a systematic review with meta-analysis to determine the effect of leukapheresis on early mortality in AML patients with hyperleukocytosis. Methods: We conducted a literature search on five databases (PubMed, EBSCOhost, Scopus, Clinicalkey, and JSTOR) up to October 2021 for studies comparing early mortality outcomes between hyperleukocytosis AML patients treated with leukapheresis versus no leukapheresis. Summary odds ratios (OR) and 95% confidence intervals (CI) were calculated using random-effects models. Heterogeneity tests were presented in I Results: Eleven retrospective cohort studies were eligible based on the inclusion and exclusion criteria. Pooled analysis showed that there was no significant difference in early mortality between patients receiving leukapheresis and not receiving leukapheresis in studies using hyperleukocytosis cutoff of 95,000/mm Conclusion: The use of leukapheresis does not provide early mortality benefit in adult AML patients with hyperleukocytosis.
MeSH term(s)	Adult ; Humans ; Leukapheresis ; Leukemia, Myeloid, Acute/complications ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/therapy ; Leukocyte Count ; Leukocytosis/complications ; Leukocytosis/mortality ; Leukocytosis/therapy ; Odds Ratio
Language	English
Publishing date	2022-01-24
Publishing country	England
Document type	Comparative Study ; Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	1341428-8
ISSN	1607-8454 ; 1024-5332 ; 1024-5340
ISSN (online)	1607-8454
ISSN	1024-5332 ; 1024-5340
DOI	10.1080/16078454.2021.2024939
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4538: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Higher peripheral blood mitochondrial DNA copy number and relative telomere length in under 48 years Indonesian breast cancer patients.

Limardi, Prisca C / Panigoro, Sonar Soni / Siregar, Nurjati Chairani / Sutandyo, Noorwati / Witjaksono, Fiastuti / Priliani, Lidwina / Oktavianthi, Sukma / Malik, Safarina G

BMC research notes

2024 Volume 17, Issue 1, Page(s) 120

Abstract: Objective: Breast cancer is the leading cause of cancer incidence and mortality among Indonesian women. A comprehensive investigation is required to enhance the early detection of this disease. Mitochondrial DNA copy number (mtDNA-CN) and relative ... ...

Abstract	Objective: Breast cancer is the leading cause of cancer incidence and mortality among Indonesian women. A comprehensive investigation is required to enhance the early detection of this disease. Mitochondrial DNA copy number (mtDNA-CN) and relative telomere length (RTL) have been proposed as potential biomarkers for several cancer risks, as they are linked through oxidative stress mechanisms. We conducted a case-control study to examine peripheral blood mtDNA-CN and RTL patterns in Indonesian breast cancer patients (n = 175) and healthy individuals (n = 181). The relative ratios of mtDNA-CN and RTL were determined using quantitative real-time PCR (qPCR). Results: Median values of mtDNA-CN and RTL were 1.62 and 0.70 in healthy subjects and 1.79 and 0.73 in breast cancer patients, respectively. We found a positive association between peripheral blood mtDNA-CN and RTL (p < 0.001). In under 48 years old breast cancer patients, higher peripheral blood mtDNA-CN (mtDNA-CN ≥ 1.73 (median), p = 0.009) and RTL (continuous variable, p = 0.010) were observed, compared to the corresponding healthy subjects. We also found a significantly higher 'High-High' pattern of mtDNA-CN and RTL in breast cancer patients under 48 years old (p = 0.011). Our findings suggest that peripheral blood mtDNA-CN and RTL could serve as additional minimally invasive biomarkers for breast cancer risk evaluation.
MeSH term(s)	Humans ; Breast Neoplasms/genetics ; Breast Neoplasms/blood ; Female ; DNA, Mitochondrial/blood ; DNA, Mitochondrial/genetics ; Indonesia ; Middle Aged ; Case-Control Studies ; Adult ; DNA Copy Number Variations/genetics ; Telomere/genetics ; Telomere Homeostasis ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Aged
Chemical Substances	DNA, Mitochondrial ; Biomarkers, Tumor
Language	English
Publishing date	2024-04-28
Publishing country	England
Document type	Journal Article
ZDB-ID	2413336-X
ISSN	1756-0500 ; 1756-0500
ISSN (online)	1756-0500
ISSN	1756-0500
DOI	10.1186/s13104-024-06783-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Change of Coagulation Status in Solid Cancer Patients Undergoing Chemotherapy in Indonesia

Noorwati Sutandyo / Lyana Setiawan

Jurnal Penyakit Dalam Indonesia, Vol 7, Iss 1, Pp 2-

A Prospective Cohort Study

2020 Volume 7

Abstract: Introduction. Cancer-associated hypercoagulability was an underlying factor of high mortality of cancer due to venous thromboembolism. Chemotherapy is proposed as one of the contributing factors of the hypercoagulable state. We aim to evaluate the change ...

Abstract	Introduction. Cancer-associated hypercoagulability was an underlying factor of high mortality of cancer due to venous thromboembolism. Chemotherapy is proposed as one of the contributing factors of the hypercoagulable state. We aim to evaluate the change of coagulation status, which was marked by D-dimer level, in cancer patients receiving chemotherapy. Methods. This is a prospective cohort study in Indonesian national cancer center which involves all adult histologically-confirmed-cancer patients who started chemotherapy between May and July 2018. The coagulation status is assessed by plasma of D-dimer level. We measured D-dimer before chemotherapy and one week after chemotherapy. Paired t-test was performed to assess the significant difference in D-dimer levels before and after chemotherapy. Results. A total of 89 patients fulfilled the eligibility criteria, of whom 74.2% were female and almost half of total subjects (44.9%) were breast cancer patients. Majority of subjects (69.6%) were stage III or stage IV cancer. There were 12.4% of subjects received cisplatin-based chemotherapy. There was a marginally significant difference in plasma level of D-dimers before and after chemotherapy (p = 0.05). We also found significant differences between D-dimer level before and after chemotherapy in stage III patients (t(35) = 2.48, p = 0.02) and stage IV patients (t(25) = 2.14, p = 0.04). There was no significant difference between D-dimer level before and after chemotherapy in stage I and stage II patients. Subgroup analyses based on chemotherapy agents showed that there was significant D-dimer change in cisplatin-based chemotherapy subjects (t(10) = 2.31, p = 0.04), but not in non-cisplatin-based chemotherapy subjects (t(77) = 1,50, p = 0.14). Conclusion. Compared to before chemotherapy, there is a significant difference of coagulation status marked by plasma D-dimer level one week after chemotherapy, particularly in patients with stage III or stage IV cancer and in patients receiving cisplatin-based chemotherapy.
Keywords	cancer ; chemotherapy ; cisplatin ; coagulation status ; Internal medicine ; RC31-1245
Language	Indonesian
Publishing date	2020-03-01T00:00:00Z
Publisher	Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Metabolic Profile and Negatively Association Between Insulin Resistance and Metastatic Incidence in Indonesian Primary Invasive Breast Cancer: A Cross-Sectional Study.

Rachman, Andhika / Fiantoro, Zaenal Hakiki / Sutandyo, Noorwati / Priantono, Dimas / Romadhon, Pradana Zaky / Jonlean, Reganedgary

International journal of general medicine

2023 Volume 16, Page(s) 3257–3265

Abstract: Introduction: Metastatic breast cancer was associated with high morbidity and mortality. Insulin resistance was hypothesized to be related to the incidence of advanced breast cancer. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and ... ...

Abstract	Introduction: Metastatic breast cancer was associated with high morbidity and mortality. Insulin resistance was hypothesized to be related to the incidence of advanced breast cancer. Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Triglyceride/Glucose Index (TyG Index) are two metrics used to measure the degree of insulin resistance. This study aims to assess the relationship between the incidence of metastatic breast cancer and insulin resistance as reflected by both metrics. Material and methods: This study is a cross-sectional study involving 150 primary invasive breast cancer patients recruited from two hospitals of different sectors from August 2019 to April 2020. Patients with double cancer and autoimmune disorder were excluded from this study. Data obtained from the patients include age, body mass index (BMI), type 2 diabetes mellitus (T2DM) status and treatment, and low-density lipoprotein (LDL) cholesterol. The electronic medical records (EMR) was consulted to find histopathology examination result, cancer staging, and any missing data. The association between HOMA-IR and TyG with metastatic incidence was analyzed using either the Mann-Whitney test (for non-normally distributed data) or the independent-sample Results: The mean of the TyG index is 8.60, and the median of HOMA-IR is 1.22. We found no significant correlation between both variables and the incidence of metastases. Conclusion: Insulin resistance was not associated with metastatic breast cancer.
Language	English
Publishing date	2023-08-01
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2452220-X
ISSN	1178-7074
ISSN	1178-7074
DOI	10.2147/IJGM.S421558
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito